Loading
Promise Bio
Promise Bio is a biotechnology company founded in 2023, focused on advancing precision medicine for autoimmune and immune-mediated diseases. The company utilizes a unique combination of epiproteomics and cloud-based artificial intelligence to enhance drug development and clinical research. Headquartered in Tel Aviv, Israel, with an office in New York, Promise Bio emerged from stealth mode in December 2024 after securing an $8.3 million seed investment. The core offering of Promise Bio is its cloud-based AI platform, known as the PromiseOS suite. This platform conducts comprehensive epiproteomic analyses on mass-spectrometry data from blood samples, detecting over 60 different post-translational modifications simultaneously. The technology supports pharmaceutical partners by identifying new drug targets, predicting treatment responses, analyzing drug mechanisms, and aiding in pathway engagement for clinical trials. Promise Bio collaborates with major pharmaceutical companies like AstraZeneca and Pfizer, as well as large hospitals and academic institutions, to drive innovation in patient care and drug discovery.
Funding
Every round, secondary, debt facility or acquisition involving Promise Bio that Lounge tracks, newest first.
No rounds recorded yet.
Paid members see the full deals desk — every AI round and exit, filterable by type, sector and country, with investors and reported ARR, plus CSV exports. Developer membership is $9/mo.
See plans →Log inKey numbers
—
0
—
—